Business Wire

RealVNC Becomes First and Only Remote Access Solution to Complete White Box Audit to Validate Security

Share

VNC Connect by RealVNC, the remote access service used by hundreds of millions of people worldwide, was audited by Cure53, the Berlin, Germany-based IT security consultancy who have also audited other industry leading software such as Mozilla VPN, 1Password and Bitwarden. The comprehensive audit, which took 86 person days and included VNC Server and VNC Viewer on Linux, Windows and Mac, VNC Viewer for iOS and Android, the VNC Connect management portal and backend services, found 38 security-relevant discoveries, none of which were critical and only three were deemed high severity, and these were fixed immediately. The report states, in conclusion, that RealVNC places a strong focus on the security posture of all its components.

“As the technologists responsible for bringing remote access to the mass market, we are today setting new standards and expectations for security in the face of the challenges of the modern IT environment. IT buyers of remote access technologies should expect no less than independent and comprehensive third-party validation of vendor claims. This is especially true for remote access software where the stakes are high, and a mistake could be reputationally damaging or even existential. With Cure53’s report, buyers can be confident that choosing RealVNC as their remote access vendor will never be a regret,” said Adam Greenwood-Byrne, CEO of RealVNC.

A white box security audit is significantly more in-depth than the more common black box penetration test (which RealVNC also commissions by an external organization annually), as the auditors have access to all of the source code, binaries and API/protocol documentation. Of the 38 vulnerabilities found across the range of software and services tested, 32 have been properly addressed — with the fixes confirmed by Cure53 — while the other six were flagged as either false-alerts or works-as-intended and evaluated to be of lower risk.

“At RealVNC, we operate from the standpoint that no company should ever take a vendor’s word for it when they claim their software is secure, which is why we chose to complete a white box audit with a highly regarded security consultancy to prove it,” said Andrew Woodhouse, CIO of RealVNC.

The Cure53 team is highly motivated to find issues when completing white box penetration tests. The fact that no critical threats were found reinforces RealVNC’s focus on ensuring its customers remain safe from threats when using VNC Connect.

“Cure53 is happy to state that test preparation, test execution and also the fix verification, which is one of the most important parts of such an audit, went smoothly and professionally. It is clear that RealVNC has demonstrated a genuine interest in ensuring VNC Connect's security and is prepared and committed to maintaining the high standards we have observed,” said Dr.-Ing. Mario Heiderich, Founder of Cure53.

Headquartered in Cambridge, RealVNC's products for desktop, mobile and embedded platforms make it easy for users to access and operate devices remotely while enabling remote users to work with technicians to resolve problems easily.

“We’re not shying away from any of the issues the report found. We actively fixed issues as they came up and, as security is an ever changing landscape, we’ll continue to ensure the security of VNC Connect in future iterations of the service,” said Ben May, Head of Cyber Security at RealVNC.

To review Cure53's summary of the audit, click here, and to learn more about why RealVNC chose to conduct a Cure53 audit, click here.

ABOUT REALVNC

RealVNC’s secure remote access and management software is used by hundreds of millions of people worldwide. Their software helps organizations cut costs and improve the quality of supporting remote devices and applications, as well as enabling remote working. RealVNC is the original, UK-based, inventor of VNC remote access software and they support an unrivaled mix of desktop, mobile and embedded platforms.

ABOUT CURE53

Cure53 offers classic black-box penetration tests (zero-knowledge) as well as white-box tests and code audits. Web application and mobile app developers speak many languages and so do we. From classic languages such as PHP, JavaScript, ActionScript, Java, Ruby, Python and Perl to more exotic candidates like web back-ends written in C++ and Delphi – we've seen them.

Since Cure53 was founded in 2007, we have performed hundreds of penetration tests against all kinds of web applications, online services, hardware interfaces, mobile applications, libraries and crypto tools. We value manual and thorough tests, human interaction and communication and a short yet-to-the-point penetration test report without overhead or pie charts no one wants to see.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lauren Meckstroth
lauren@theabbiagency.com
702.499.7388

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia8.12.2025 15:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice. “At ASH 2025, we will present new data from across our CLL franchise, highlighting both the strength of BRUKINSA and the potential of BGB-16673,” said Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne. “Long-term data are the gold standard in CLL, and BRUKINSA continues to deliver the high levels of durable progression-free and overall survival that patients and physicians should demand from a BTK inhibitor. BGB-16673, the most advanced BTK degrader in the clinic with over 800 patients dosed to date, potentially repres

Pink Changing Lives ® : Mary Kay Builds 11 th Preschool in Sri Lanka, Turning a Dream Into Thousands of New Beginnings8.12.2025 15:00:00 EET | Press release

Mary Kay Inc., a global champion for women’s empowerment, is turning pink into purpose through its Pink Changing Lives® Program to raise awareness and funds to support life-changing programs advancing cancer research, support survivors of domestic violence, protect our planet’s most precious resources, and create opportunities that help women and their families thrive. Since 1996, the multi-faceted Pink Changing Lives® Program has donated over $230 million in monetary and in-kind donations to improve the lives of women and their families in communities around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208554750/en/ Mary Kay Inc., a global champion for women’s empowerment, is turning pink into purpose through its Pink Changing Lives® Program to raise awareness and funds to support life-changing programs advancing cancer research, support survivors of domestic violence, protect our planet’s most precious reso

AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies8.12.2025 15:00:00 EET | Press release

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced it has received the first delivery of high-activity 228Th, the parent isotope of 212Pb and a key starting material to produce the alpha-emitter 212Pb, used to manufacture ADVC001, the company’s lead asset, and other 212Pb-based radioligand therapies in the pipeline. This delivery marks a major milestone for the company and underscores the industry leading infrastructure and operational capabilities in place at the flagship facility in Brisbane, Australia – supported by a highly specialized and experienced team with unique industry expertise. This distinct capability gives AdvanCell a strong competitive edge as it accelerates the scale-out of 212Pb production in view of the rapid advancement of ADVC001 clinical development and the expanding pipeline. The received 228Th will be processed into sources for the company’s proprietary generator and installed in pr

From Pilots to Profit: NTT DATA's 2026 Global AI Report Shows How Top Performers Turn AI Vision Into Value8.12.2025 15:00:00 EET | Press release

NTT DATA, a global leader in AI, digital business and IT services, today released the 2026 Global AI Report: A playbook for AI leaders. The playbook is based on the company’s new benchmark research and reveals how “AI leaders” are separating from competitors through strategy and execution. The analysis is based on a survey of 2,567 senior executives across 35 countries and 15 industries. Only 15% of participating organizations qualified as “AI leaders,” defined by clear AI strategies, mature operating models and focused execution. These leaders report significantly higher revenue growth and profit margins than other organizations. “AI accountability now belongs in the boardroom and demands an enterprise-wide agenda,” said Yutaka Sasaki, President and CEO, NTT DATA Group. “Our research shows that a small group of AI leaders already are using AI to differentiate, grow and reinvent how humans and machines create value together.” Strategy Leaders treat AI as a core growth engine and rewire

IonQ Expands in EU With Slovakia’s First National Quantum Communication Network8.12.2025 14:05:00 EET | Press release

IonQ (NYSE: IONQ), the world’s leading quantum company, through its subsidiary ID Quantique (IDQ), today announced the deployment of Slovakia’s first national quantum communication network. Developed in partnership with the Institute of Physics, Slovak Academy of Sciences (IPSAS), the new system features a resilient hybrid architecture designed to strengthen the country’s cybersecurity infrastructure and support Europe’s quantum digital programs. The Slovak Quantum Communication Infrastructure (skQCI) project represents a major milestone in Slovakia’s contribution to the European Quantum Communication Infrastructure (EuroQCI) initiative, which seeks to establish a secure quantum-resistant communication backbone covering all European Union (EU) member states and territories. By integrating quantum-safe technologies at a national scale, Slovakia will directly reinforce the security of its most critical institutions. “The skQCI project is a strategic milestone in fortifying the digital so

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye